Follicular lymphoma (FL) is associated with a variable pattern of relapse, with shorter durations of response and progression-free survival seen with each subsequent treatment. As a result of this relapsing pattern, the care of patients with FL generally requires multiple lines of therapy with alternative mechanisms of action—including the lenalidomide/rituximab regimen, an EZH2 inhibitor, various phosphatidylinositol-3-kinase (PI3K) inhibitors, chimeric antigen receptor (CAR) T-cell therapies, and, for patients interested in participating in clinical trials, investigational therapies. To optimize patient outcomes, it is important to be aware of which patient and disease characteristics to consider when sequencing such a large range of treatment options along with the mechanism of action and adverse events associated with each agent. In this video lecture, an expert discusses management strategies for patients with FL through the lens of clinical trial data along with real-world patient case narratives.
Interactive video lecture
After completing this activity, participants should be better able to:
- Summarize efficacy and safety evidence for novel therapies for relapsed/refractory follicular lymphoma (RRFL)
- Identify patient and disease factors that can impact treatment selection in RRFL
- Apply recommendations to identify and manage toxicities of novel agents for RRFL
Oncology NPs, PAs, and nurses
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
NP course advisor: Beth Sandy, MSN, CRNP, Abramson Cancer Center, Philadelphia, Pennsylvania
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until January 30, 2023. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Jessica Garner, DMSc, PA-C, University of the Pacific, Sacramento, California
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This program was cosupported by educational grants from Bristol-Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Merck & Co., Inc; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.
This activity is supported by educational grants from Bristol-Myers Squibb and Novartis Pharmaceuticals Corporation.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose to the audience all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Burke: consulting fees: AbbVie, Adaptive Biotechnologies, AstraZeneca, Bristol-Myers Squibb, Epizyme, Kura, Kymera Therapeutics, MorphoSys, Roche/Genentech, Verastem Oncology, X4 Pharmaceuticals; consulting fees/fees for non-CME/CE services: BeiGene, Seagen.
Ms Sandy: fees for non-CME/CE services: Amgen, AstraZeneca, Jazz, Merck, Takeda.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose, except Ms Sandy as noted above.
Participants wishing to earn CE/CME credit must:
- View the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
The estimated time to complete this activity is 1.00 hour.
Release date: January 31, 2022
Expiration date: January 30, 2023
© 2022 Practicing Clinicians Exchange. All Rights Reserved. 100721O-7G